Advertisement

European Journal of Clinical Pharmacology

, Volume 13, Issue 3, pp 163–170 | Cite as

Haemodynamic and tolerance studies in man of a new, orally active, selectiveβ1-adrenoceptor agonist H 80/62

  • G. Johnsson
  • L. Jordö
  • P. Lundborg
  • O. Rönn
  • Ingegerd Welin-Fogelberg
  • J. Wikstrand
Originals

Summary

The selective β1-adrenoceptor agonist H 80/62 was administered intravenously and orally to healthy subjects and its effects on systolic time intervals, arterial blood pressure and heart rate were studied. Side-effects were noted too, and continuous ECG-recordings were made in order to study its arrhythmogenic effect. After i.v. administration of H 80/62 20 µg/kg body weight there was shortening of total electromechanical systole, the pre-ejection period and of the left ventricular ejection time, systolic blood pressure tended to increase, and diastolic blood pressure and heart rate were essentially unchanged. When administered orally as a sustained-release preparation in doses between 20 and 40 mg the haemodynamic effects were qualitatively the same as after i.v. administration, but in some studies there was a slight increase in heart rate. During exercise the systolic blood pressure and heart rate were identical after H 80/62 and placebo. The effect of the drug was maximal immediately after cessation of the i.v. infusion and basal values were regained within 60 min. After oral administration of a sustained-release formulation the effect was maximal after one hour and persisted for at least five to seven hours. The drug was well tolerated on repeated administration. The incidence of ventricular extrasystoles was possibly increased in one subject out of eight (11 ventricular extrasystoles during 18 h). The results of this Phase I study of H 80/62 warrant further evaluation of the drug in man.

Key words

H 80/62 haemodynamic effects noninvasive techniques selectivity β1-adrenoceptor agonist man 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahmed, S. S., Levinson, G. E., Schwartz, C. J., Ettinger, P. O.: Systolic time intervals as measures of the contractile state of the left ventricular myocardium in man. Circulation46, 559–571 (1972)Google Scholar
  2. 2.
    Brittain, R. T., Jack, D., Ritchie, A. C.: Recent β-adrenoceptor stimulants. Adv. Drug Res.5, 197–253 (1970)Google Scholar
  3. 3.
    Brodsky, M., Delon, W. U., Denes, P., Kanakis, C., Rosen, K. M.: Arrhythmias documented by 24 h continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am. J. Cardiol.39, 390–395 (1977)Google Scholar
  4. 4.
    Carlsson, E., Åblad, B., Brändström, A., Carlsson, B.: Differentiated blockade of the chronotropic effects of various adrenergic stimuli in the cat heart. Life Sci.11, Part I, 953–958 (1972)Google Scholar
  5. 5.
    Carlsson, E., Dahlöf, C.-G., Hedberg, A.: Differentiation of cardiac chronotropic and inotropic effects ofβ-adrenoceptor agonists. Naunyn Schmiedebergs Arch. Pharmacol.300, 101–105 (1977)Google Scholar
  6. 6.
    Farmer, J. B., Levy, G. P., Marshall, R. J.: A comparison of the β-adrenoceptor stimulant properties of salbutamol, orciprenaline and soterenol with those of isoprenaline. J. Pharm. Pharmacol.22, 945–947 (1970)Google Scholar
  7. 7.
    Johansson, R., Regardh, C.-G., Sjögren, J.: Absorption of alprenolol in man from tablets with different rates of release. Acta pharm. suec.8, 59–70 (1971)Google Scholar
  8. 8.
    Johnsson, G.: Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work. Acta Pharmacol. Toxicol. (Kbh)36, Suppl V, 59–68 (1975)Google Scholar
  9. 9.
    Knaus, M., Pfister, B., Dubach, U. C., Imhof, P. R.: Human-pharmacology studies with a new, orally active stimulant of cardiac adrenergic β-receptors (C 50,005/A-Ba). Am. Heart J. (in press) (1978)Google Scholar
  10. 10.
    Roble, N. W., Nutter, D. O., Moody, C., NcNay, J. L.: In vivo analysis of adrenergic receptor activity of dobutamine. Circulat. Res.34, 663–671 (1974)Google Scholar
  11. 11.
    Tuttle, R. R., Mills, J.: Development of a new catecholamine to selectively increase cardiac contractility. Circulat. Res.36, 185–196 (1975)Google Scholar
  12. 12.
    Weissler, A. M., Kamen, A. R., Bornstein, R. S., Schoenfeld, C. D., Cohen, S.: The effect of deslanoside on the duration of the phases of ventricular systole in man. Am. J. Cardiol.15, 153–161 (1965)Google Scholar
  13. 13.
    Weissler, A. M., Harris, W. S., Schoenfeld, C. D.: Bedside technics for the evaluation of ventricular function in man. Am. J. Cardiol.23, 577–583 (1969)Google Scholar
  14. 14.
    Wikstrand, J.: Non-invasive assessment of cardiac function. Studies in normotensive and hypertensive 50-year-old men and male infarction patients aged 48–57 (Available on request). Thesis, Göteborg, Sweden (1976)Google Scholar
  15. 15.
    Wikstrand, J., Nilsson, K., Wallentin, I.: Distortion of non-invasive cardiac pulse curves. A capillary-damped pick-up and a calibration unit for apexcardiograms and other pulse curves. Br. Heart J.29, 995–1005 (1977)Google Scholar

Copyright information

© Springer-verlag 1978

Authors and Affiliations

  • G. Johnsson
    • 3
  • L. Jordö
    • 2
  • P. Lundborg
    • 3
  • O. Rönn
    • 2
  • Ingegerd Welin-Fogelberg
    • 2
  • J. Wikstrand
    • 1
  1. 1.Department of Clinical PhysiologySahlgren's HospitalGöteborgSweden
  2. 2.Department of Medicine IISahlgren's HospitalGöteborgSweden
  3. 3.the Research LaboratoriesAB HässleMölndalSweden

Personalised recommendations